Woes for Mass. biotech council

Written byAlison McCook

| 1 min read

The $1 billion linkurl:life sciences initiative;http://www.the-scientist.com/news/display/53359/ posed by Massachusetts Governor Deval Patrick is dealing with some scrutiny lately. The new president of the Massachusetts Biotechnology Council faces a state ethics investigation about his transition from the public to the private sector, and has declined to publicly discuss the bill. Massachusetts Biotechnology Council President Robert Coughlin has announced he will not publicly discuss the bill, since, as a former state employee (he was a state representative from Dedham and the governor's undersecretary of business development) he cannot lobby the legislature until next year, according to the Boston Globe. He said he plans to avoid lobbying the state government until September, one year after he joined the council, and will focus his lobbying at the federal level, where he has no restrictions. Also linkurl:according to;http://www.boston.com/business/globe/articles/2007/11/30/for_biotech_chief_mums_the_word?mode=PF the Globe, Coughlin continued acting as Patrick's point person on the life sciences initiative without telling his bosses that he was also vying for the presidency of the council, which comes with a $500,000 salary. He is facing a State Ethics Commission investigation about his hiring. Coughlin's predecessor, Thomas Finneran, linkurl:stepped down;http://news.bostonherald.com/news/regional/politics/view.bg?articleid=1047330 in January when he pled guilty to obstruction of justice, about false testimony he gave in 2001 over voter redistricting. It was recently revealed that he received a performance bonus of nearly $50,000.

Woes for Mass. biotech council

The Scientist ARCHIVES

Become a Member of

Meet the Author

Alison McCook

Related Research Resources

A Stubborn Gene, a Failed Experiment, and a New Path

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies